ICCCImmuCell Corporation

$60M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+110.6% YoY

Gross Profit

$2M31.6% margin

Operating Income

-$300,050-4.1% margin

Net Income

-$437,868-6.0% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+42.4%

Cash Flow

Operating Cash Flow

$418,505

Free Cash Flow

$348,149

Stock-Based Comp.

$81,110

Balance Sheet

Total Assets

$43M

Total Liabilities

$18M

Stockholders' Equity

$25M

Cash & Equivalents

$960,347

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$3M	+110.6%
Gross Profit	$2M	$300,775	+663.1%
Operating Income	-$300,050	-$2M	+86.7%
Net Income	-$437,868	-$2M	+81.1%

Geographic Segments

UNITED STATES

$6M100%

ICCC Q1 2024 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena